Tuesday, 24 April 2018 - 0:08
  • it
  • de
  • en
  • fr


Positive momentum for Novo: Ozempic (semaglutide) approved

Novo Nordisk yesterday announced that FDA has approved Ozempic (semaglutide), GLP-1’s analog, and the Danish group’s shares have soon risen over 3% (Copenhagen). Ozempic is proposed as a once-weekly injection. The new product will be sold at $676 per prescription….

Novo focuses on new obesity therapy Semaglutide

Novo Nordisk reiterated last week, during a presentation to investors and analysts, the importance of its new investigational obesity therapy semaglutide for its future. Novo recently completed a Phase II clinical trial with semaglutide vs Saxenda vs Placebo, enrolling 1,000…

Novo Nordisk applies to FDA and EMA for approval of semaglutide

Novo Nordisk announced it submitted a NDA (New Drug Application) to the FDA and a MAA (Marketing Authorisation Application) to the EMA for semaglutide, a new GLP-1 analogue to be administered only once-weekly. The product is intended for the treatment…